Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals
Timely diagnosis of rheumatoid arthritis (RA) allows for prompt initiation of treatment—an important component in increasing the likelihood of clinical remission. Attaining clinical remission, or the secondary goal of low disease activity, in turn helps limit joint damage and subsequent disability as well as other unwelcome consequences of RA. This case presentation depicts a patient’s journey toward remission, using the “treat to target” approach advocated by American and European RA management guidelines.
Rheumatologists, physician assistants, and nurse practitioners
After completing the activity, the participant should be better able to:
Recognize the full spectrum of RA manifestations, including the impact on functional ability, quality of life, and elevated risk for myocardial infarction and stroke
Implement guidelines-directed, treat to target strategies to achieve RA remission or low disease activity
Incorporate shared decision-making strategies in RA treatment decisions
Individualize RA treatment plans with consideration for patient-centric issues such as tolerability and likelihood of adherence in addition to efficacy and safety
Conflict Of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
Roy Fleischmann, MD, MACR - Chair Medical Director Metroplex Clinical Research Center Clinical Professor of Medicine University of Texas Southwestern Medical Center Dallas, Texas, USA
Dr. Fleischmann reports that he is a consultant for AbbVie Inc., Amgen Inc., Eli Lilly, GlaxoSmithKline plc, Pfizer Inc., and Sanofi USA and receives fees for non-CME services from Pfizer Inc. He also receives research grants from AbbVie Inc., Amgen Inc., Eli Lilly, GlaxoSmithKline plc, Novartis, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi USA, Samumed LLC, and UCB Inc.
Bernard Combe, MD, PhD Professor of Rheumatology Montpellier University Head, Bone and Joint Department Montpellier University Hospital Montpellier, France
Dr. Combe reports that he is a consultant for and is on the speakers’ bureaus of AbbVie Inc., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co. Ltd., Janssen, Lilly, Merck Sharp & Dohme Corp., Pfizer Inc., and UCB Inc. He also receives research funds from Chugai Pharmaceutical Co. Ltd., Merck Sharp & Dohme Corp., and Pfizer Inc.
Accredited Provider Disclosures
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
Publishing Staff Disclosures
Lori Marrese and Jill Rovitzky Black have nothing to disclose in regard to commercial support.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education, Sanofi Genzyme, and Regeneron Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To receive credit for this activity, the participant must complete the pre-activity questionnaire, post-test, and program evaluation. Participants must also score at least 70% on the post-test. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.